T he arterial media comprises vascular smooth muscle cells (VSMCs; ≈30%) and extracellular matrix (ECM, ≈70%), including collagen, elastin, and matrix glycosaminoglycans. The intima in atherosclerosis also comprises both cellular and noncellular components, and advanced plaques show large acellular regions. VSMCs synthesize both filamentous and nonfilamentous ECM components, and chronic low-level VSMC apoptosis promotes medial degeneration characterized by VSMC loss, elastin fragmentation, and ECM degradation.
T he arterial media comprises vascular smooth muscle cells (VSMCs; ≈30%) and extracellular matrix (ECM, ≈70%), including collagen, elastin, and matrix glycosaminoglycans. The intima in atherosclerosis also comprises both cellular and noncellular components, and advanced plaques show large acellular regions. VSMCs synthesize both filamentous and nonfilamentous ECM components, and chronic low-level VSMC apoptosis promotes medial degeneration characterized by VSMC loss, elastin fragmentation, and ECM degradation. 1 Medial VSMC apoptosis, elastin fragmentation, and matrix degradation also occur in arterial aneurysms, vascular injury, and vascular remodeling. ECM degradation after VSMC apoptosis may be because of impaired synthesis from fewer VSMCs, increased degradation during VSMC apoptosis, or both processes triggered by the same stimuli. Indeed, macrophages induce VSMC apoptosis and secrete MMP (matrix metalloproteinase) enzymes that degrade ECM in atherosclerosis. However, macrophages are frequently absent in medial degeneration or vascular remodeling, and the mechanisms that might directly link VSMC apoptosis with ECM degradation in vascular disease are unclear.
Apoptosis is regulated via integration of pro and antiapoptotic signals. IGF-1 (insulin-like growth factor 1) is a potent survival factor for VSMCs 2, 3 through activation of the serine/theronine kinase Akt1 (serine threonine kinase of the Akt family). Akt1 protects against VSMC apoptosis and atherogenesis and also promotes fibrous cap formation and reduces necrotic cores. 4, 5 Akt1-induced protection is due in part via phosphorylation of the FOXO (forkhead transcription factor O) subfamily, leading to their association with 14-3-3 proteins and retention in the cytoplasm; survival factor withdrawal leads to FOXO dephosphorylation, nuclear translocation, and activation. 6, 7 The mammalian FOXO subfamily includes 4 members: FOXO1, 3a, 4, and 6. 8, 9 FOXOs are involved in a complicated signaling network, and their transcriptional targets regulate multiple physiological and pathological processes, including cancer, development, mitochondria-dependent and independent oxidative stress, DNA repair, and cell cycle arrest. 10 However, FOXOs are strictly cell type-specific, and their effects depend on expression levels. For example, FOXO3a protects cells from oxidative stress and DNA damage, but sustained FOXO3a activation leads to apoptosis, and FOXO3a activation induces apoptosis in hematopoietic cells but cell cycle arrest in most other cell types. 11, 12 VSMCs in human atherosclerotic plaques show reduced IGF-1 receptor expression 13 and phosphorylation of both Akt and FOXO3a, indicating FOXO3a activation.
14 Massive overexpression of FOXO3a via adenovirus-mediated gene transfer inhibits neointimal hyperplasia by promoting p27 (cyclin dependent kinase inhibitor p27)-mediated cell cycle arrest and apoptosis 11, 12 and prevents VSMC migration through inhibition of CYR61 (cysteine-rich angiogenic inducer 61). 15 However, the functional consequences of activation of endogenous or low levels of FOXO3a in atherosclerosis, and in particular whether FOXO3a links VSMC apoptosis and ECM degradation, are unknown.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

FOXO3a Induces VSMC Apoptosis and MMP13 Expression and Activation
We first generated rat VSMCs expressing N-terminal haemagglutinin-tagged FOXO3aA3ER. 5 FOXO3a is inhibited by Akt phosphorylation of 3 serine residues, but their mutation to alanine renders FOXO3a insensitive to Akt (FOXO3aA3). FOXO3aA3ER is thus a hydroxytamoxifen-activatable human FOXO3aA3 allele allowing temporal FOXO3a activation. FOXO3aA3ER was inactive without hydroxytamoxifen, but hydroxytamoxifen induced FOXO3a targets such as bim, caused FOXO3a translocation to the nucleus within 4 hours, and induced >80% apoptosis within 24 hours, defined by chromatin condensation on DAPI (4',6-diamidino-2-phenylindole) staining and characteristic appearances on digital videomicroscopy ( Figure I in the online-only Data Supplement). To examine downstream signaling after FOXO3aA3ER activation, we examined mRNA expression from FOXO3aA3ER VSMCs and control wild-type rat VSMCs 4 hours after hydroxytamoxifen treatment by microarray 5 ( Table I in the online-only Data Supplement; full data at http://www.bioc. cam.ac.uk/littlewood/foxo3a-microarray/view). Of 27 342 genes, 3467 were upregulated and 4412 genes downregulated 4 hours after hydroxytamoxifen in FOXO3aA3ER VSMCs. In addition to bona fide FOXO3a target genes (bim, gadd45α, p27), other apoptosis and antiapoptosis genes, such as bcl2, were upregulated, demonstrating the complexity of FOXO3a regulation of apoptosis. However, several MMPs were also upregulated, and downregulated genes included those associated with ECM attachment and MMP inhibitors. In particular, there was marked induction of mmp13 (371-fold) and downregulation of timp3 (27-fold), which would result in markedly increased MMP activity, especially MMP13 (Table I in the  online-only Data Supplement) .
To confirm the microarray data, we examined mmp13 mRNA and protein by quantitative polymerase chain reaction and Western blotting after hydroxytamoxifen treatment ≤24 hours. FOXO3a activation in FOXO3aA3ER VSMCs induced mmp13 mRNA in a time-dependent pattern (78-fold at 12 hours; Figure 1A) , with a lower but significant induction of other FOXO3a targets (gadd45α [21- Figure 1B) . Zymography of the conditioned media confirmed that MMP13 showed the largest change in activity after hydroxytamoxifen ( Figure 1C) , and immunoprecipitation of the conditioned media with an MMP13 antibody and subsequent zymography showed significantly increased MMP13 activity after hydroxytamoxifen ( Figure 1D ). In situ zymography showed that hydroxytamoxifen induced degradation of fluorescent-labeled fluorogenic dye-quenched gelatin around FOXO3aA3ER cells ( Figure 1E ). FOXO3a activation also inhibited expression of TIMP1/2/3 (tissue inhibitors of MMP1/2/3) in cell lysates, with a particularly marked time-dependent reduction in TIMP3 ( Figure II in the online-only Data Supplement). 
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MMP13 Is a Bona Fide FOXO3a Target in VSMCs
The rapid induction of MMP13 in FOXO3aA3ER VSMCs suggests that MMP13 is a direct FOXO3a transcriptional target. Indeed, mmp3, mmp9, and mmp2 promoters show putative FOXO-binding sites, although their activity varies markedly according to cell type. 16, 17 We cotransfected full-length (−1→−1600 promoter region relative to the transcriptional start site) MMP13-, MMP2-, MMP3-, or MMP9-luciferase plasmids with pRenilla-cytomegalovirus into FOXO3aA3ER VSMCs (Table II in 
FOXO3a Activation at Endogenous Levels Induces MMPs and ECM Degradation
Although FOXO3a overexpression studies in rodent cells can elucidate possible FOXO3a targets and functional activity, FOXO3a targets and effects depend on cell type, species, level of expression, and activity. We, therefore, examined the effects of activation of endogenous levels of FOXO3a in human VSMCs by withdrawal of serum±glucose, which reduces Akt-dependent phosphorylation. 13 Transfer of human VSMCs to serum-free (SF) medium reduced phosphorylated FOXO3a with no change in total FOXO3a; in contrast, complete loss of p-FOXO3a was seen after serum and glucose withdrawal (SFGF), indicating full activation of endogenous FOXO3a ( Figure 2E ). SFGF induced almost complete nuclear localization of FOXO3a and increased mRNA expression of bim (1.5-fold) and gadd45α (18- to FOXO3a, or the MMP13-selective inhibitor WAY170523 (Figure VIE through VIH in the online-only Data Supplement), confirming that activation of endogenous levels of FOXO3a induces MMP13 expression and activity in human VSMCs, which is sufficient to promote apoptosis.
FOXO3a-Induced Apoptosis Is Mediated, in Part, by MMP13-Induced ECM Degradation and Fibronectin Cleavage
Although FOXO3a induces transcription of many proapoptotic genes, the ECM also provides survival signals, such that degradation of ECM proteins may promote VSMC apoptosis.
To determine whether FOXO3a-induced MMP13 degrades ECM survival proteins, we first examined a range of MMP inhibitors on FOXO3a-induced MMMP13 activation and activity, including the broad-spectrum MMP inhibitors GM6001 and Batimastat, the MMP13-selective inhibitors WAY170523 and M13i, and the serine protease inhibitor aprotinin. In particular, WAY170523 has an IC 50 of 17 nM for MMP13 with >5800-, 56-, and >500-fold selectivity against MMP1, MMP9, and TACE (TNF-α-converting enzyme), respectively. 18 GM6001, Batimastat and WAY170523 inhibited MMP13 cleavage in conditioned media and activity on zymography, whereas M13i partly reduced MMP13 cleavage but not its activity ( Figure 
SM22αFOXO3aA3ER Mice
To examine the role of FOXO3a in VSMCs in vivo, we generated SM22αFOXO3aA3ER transgenic mice. Haemagglutinintagged FOXO3aA3ER was coupled to the minimal SM22α promoter lacking the G/C-rich repressor region (−256 to −249; Figure 3A ). This promoter (−447 to +89 relative to the transcriptional start site) directs expression of transgenes only to VSMCs of large-and medium-sized arteries in adult mice, with no expression in venous or visceral SMCs, 20 whereas G/C-rich region mutation prevents promoter downregulation in atherosclerosis and vessel remodeling. 21 Two SM22αFOXO3aA3ER founder lines were established, which were viable, fertile, transmitted the transgene normally, and had no overt phenotype without tamoxifen. SM22αFOXO3aA3ER was expressed only in arteries, but not in heart, liver, or gut ( Figure 3B) , and in cultured VSMCs of transgenic but not littermate control mice. SM22αFOXO3aA3ER activation did not affect expression of other FOXO species but induced bim, gadd45α, mmp2, and mmp13 and also induced apoptosis ( Figure IX in the onlineonly Data Supplement). Thus, SM22αFOXO3aA3ER is expressed, activated by hydroxytamoxifen, and induces transcription of FOXO3a target genes and apoptosis in VSMCs both in vitro and in vivo.
We treated SM22αFOXO3aA3ER and wild-type littermate control mice with tamoxifen (1 mg immunoprecipitation daily for 3 days) and examined FOXO3a expression, FOXO3a nuclear localization, and apoptosis in aortas at 7 days. FOXO3aA3ER expression was evident in transgenic mouse aortas at low levels compared with endogenous FOXO3a and with no change in expression of endogenous FOXO3a ( Figure 3C ). Tamoxifen treatment resulted in predominantly nuclear FOXO3a localization in SM22αFOXO3aA3ER mice compared with predominantly cytoplasmic localization in control mice ( Figure 3D ; quantified in Figure IXD in the onlineonly Data Supplement). In SM22αFOXO3aA3ER mouse aortas, Tamoxifen induced VSMC apoptosis ( Figure 3E and 3F), increased mmp13 mRNA expression 4-fold, and also induced MMP13 protein expression ( Figure 3G ) and activity ( Figure 3H ). MMP13 activity could be inhibited by concomitant treatment with WAY170523, which had no effect on MMP2 or MMP9 activity ( Figure 3H ).
FOXO3a Activation Leads to VSMC Apoptosis and Promotes Atherosclerosis
To examine the effect of FOXO3a activation during atherogenesis, SM22αFOXO3aA3ER mice were crossed with ApoE −/− (apolipoprotein E deficient) mice, and homozygous male SM22αFOXO3aA3ER/ApoE −/− or littermate control ApoE −/− mice were fat fed for 14 weeks from 8 to 22 weeks of age. Both groups received hydroxytamoxifen administered triweekly for 14 weeks and bromodeoxyuridine for the last 2 weeks. Serum lipids were measured before and after 7 and 14 weeks of fat feeding. Blood pressure was measured by tail cuff. Atherosclerosis was examined in the aortic roots, brachiocephalic arteries, and descending aorta at 22 weeks (14 weeks of fat feeding), which show different degrees of plaque development. Body weight, serum lipids (Table III in the online-only Data Supplement), heart rate, blood pressure (Table IV in 
FOXO3a Activation Promotes Apoptosis and Neointima Formation, Mediated, in Part, by MMP13
Our data indicate that FOXO3a activation induces apoptosis and MMP13 activity in vitro and in vivo that can be inhibited by the MMP13 inhibitor WAY170523 and promotes atherogenesis, increased necrotic core area, reduced relative fibrous cap area, increased apoptosis, and medial degeneration. However, it does not identify whether MMP13 mediates any of the effects of FOXO3a activation in vivo. We, therefore, examined the effect of FOXO3a on remodeling after carotid artery ligation-a well-established model that features medial VSMC apoptosis and MMP activation. 22 Both final vessel caliber and neointimal size are regulated by VSMC apoptosis in this model, 23 and the neointima formed is mostly VSMCs derived from the media. 24 Male SM22αFOXO3aA3ER and control littermate mice aged between 5 and 6 months underwent carotid artery ligation followed by tamoxifen treatment 3× per week to ensure that FOXO3aER is activated throughout the whole time course during remodeling, with or without WAY170523 administered continuously by osmotic minipump from days 0 to 7 after ligation, at a WAY170523 concentration that inhibits MMP13 activity in vivo ( Figure 3H ). Bromodeoxyuridine was administered throughout. FOXO3a activation increased intimal area and cell count compared with control vessels-an effect that was reduced by WAY170523-with no effect of FOXO3a activation or WAY170523 on lumen area, medial area, or medial cell count ( Figure 6 ; Table VII in the online-only Data Supplement). However, WAY170523 reduced medial cellularity, suggesting that it protects against matrix degradation. FOXO3a activation increased VSMC proliferation, which was also reduced by WAY170523 (Figure 6 ; Table VII in the online-only Data Supplement). WAY170523 did not affect intimal or medial areas or cell proliferation in the absence of FOXO3a activation in control mice. In contrast, FOXO3a activation in SM22αFOXO3aA3ER mice increased apoptosis compared with control mice, and WAY170523 reduced apoptosis in both control and SM22αFOXO3aA3ER mice ( Figure 6 ; Table VII in the online-only Data Supplement).
Discussion
FOXO3a activity is increased in VSMCs in human atherosclerotic plaques, and previous studies have demonstrated that Akt1 in VSMCs protects against atherosclerosis 4, 5, 25, 26 ; however, the major targets of Akt protection in atherosclerosis are not known. Specifically, FOXO3a has multiple transcriptional targets in a large range of cellular processes, and its effects are cell type specific. Both apoptosis and MMP activity occur in human plaques and often colocalize to the necrotic core, where they have been ascribed to macrophages. However, although VSMCs can generate foam cells in atherosclerosis, 27 no link between VSMC apoptosis and MMP expression or activity has been shown or the mechanism determined.
There are several important findings from our study. FOXO3a activation markedly induces MMP13 expression and secretion from VSMCs, and MMP13 (but not MMP3 or 9) is a direct FOXO3a transcriptional target in VSMCs. FOXO3a reduces TIMP1-3 expression at both RNA and protein levels, which could further increase MMP activity. FOXO3a activation causes VSMC apoptosis and ECM breakdown, both of which, in part, require MMP13. Importantly, activation of endogenous levels of FOXO3a induces MMP13 expression, secretion, activation, ECM breakdown, and apoptosis, and MMP13 inhibitors reduce FOXO3a-induced apoptosis, confirming that FOXO3a-mediated apoptosis in VSMCs is because of both induction of conventional proapoptotic genes and MMP-induced ECM breakdown of protective proteins, including fibronectin. FOXO3a activation in SM22αFOXO3aA3ER mice induces VSMC apoptosis, increases MMP13 expression and activity, promotes atherosclerosis, increases necrotic core and reduces relative fibrous cap areas, and promotes medial degeneration. Finally, FOXO3a activation in VSMCs increases intimal formation, associated with increased apoptosis and compensatory increased VSMC proliferation; MMP13 inhibition reduces VSMC apoptosis and intimal and medial VSMC proliferation induced by FOXO3a and reduces neointima formation.
The MMPs are 23 secreted or cell surface proteases that hydrolyze ECM components. MMP groups are based on overlapping ECM substrates, for example, collagenase (MMP1, 8, 13), gelatinases (MMP2, 9), and stromelysins (MMP3, 7, 10, 11). MMPs may facilitate VSMC migration and vessel remodeling in early atherosclerosis but degrade ECM in advanced plaques to promote plaque vulnerability. 28 Expression of some MMPs is increased in atherosclerosis together with reduction in TIMPs in both mice and humans, associated with increased conversion of zymogens to activated proteases. 28 In particular, atherosclerotic plaques and arterial aneurysms have increased MMP13 activity, 29, 30 and MMP13-null mice have increased fibrillar collagen. 31, 32 Although these findings suggest that MMP13 may be important in atherosclerosis, previous studies have identified macrophages as the likely source, 29 and MMP13 has not been linked with FOXO3a activation in VSMCs. In contrast, although the absolute increase in mmp13 mRNA by array or quantitative polymerase chain reaction differed, most likely related to different techniques, we show that FOXO3a activation caused marked release and activity of MMP13 from VSMCs.
The endogenous pathways that protect against VSMC apoptosis in atherosclerosis have not been studied extensively. We find that FOXO3a activation induces apoptosis and ECM degradation through MMP13 in transgenic mice and cultured VSMCs expressing a constitutively active chimeric protein but importantly also with endogenous levels of FOXO3a. Endogenous FOXO3a is activated in human atherosclerosis, 14 and in culture induces MMP13 induction and secretion, ECM breakdown, and VSMC apoptosis. Endogenous FOXO3a inhibitors are also reduced in atherosclerosis and plaque VSMCs, including Akt [13] [14] [15] and the deacetylase sirtuin 1. 33, 34 Indeed, VSMC-specific SIRT1 deletion promotes atherosclerosis, VSMC apoptosis, and marked medial degeneration, elastin breaks and aneurysm formation in mice. 34 The combination of reduced FOXO3a inhibitors, increased MMP activation, and reduced TIMP expression induced by FOXO3a would have profound effects on ECM integrity in atherosclerosis in vivo. In addition, as VSMCs synthesize ECM in the vessel wall, FOXO3a-induced VSMC apoptosis might further reduce ECM formation.
We find major effects of FOXO3a in vessel remodeling and neointima formation after carotid artery ligation. This model is characterized by MMP9 activity (days 1-3), VSMC apoptosis (days 2-14), and MMP2 activity (days 14-28), associated with medial recovery, neointimal formation, and arterial remodeling. 22 Augmenting VSMC apoptosis significantly increases cell proliferation-an example of apoptosis-induced compensatory proliferation, cell migration, and ECM synthesis, resulting in increased neointimal and medial areas. 23 We find that FOXO3a activation increases neointima formation, intimal and medial proliferation, and VSMC apoptosis, all of which were reduced by MMP13 inhibition, indicating that MMP13 partly regulates the effect of FOXO3a activation on remodeling.
There are several limitations to our study. For example, we used an overexpression system both in vitro and in vivo to examine FOXO3a effects in VSMCs, which may not be subject to the same regulatory controls and, therefore, not truly reflect activation of endogenous FOXO3a. However, the levels of transgene expression in vivo are low, and we show that activation of FOXO3aA3ER and LY294002-induced FOXO3a activation do not result in compensatory changes in expression of other FOXO species. In addition, our studies have focused on the effects of FOXO3a activation in advanced atherosclerosis and have not examined early phases of atherogenesis. However, FOXO3a is not activated until later stages of atherosclerosis, 14 and VSMC apoptosis is not seen in human atherosclerosis until advanced lesions are present. 35 The presence of activated FOXO3a in atherosclerosis 14 and the marked activation and effects of MMP13 might suggest that MMPs in general and MMP13 in particular are attractive therapeutic targets. However, no MMP inhibitor has been approved clinically for atherosclerosis, 36 which may reflect differing roles of MMPs in plaque development, MMP redundancy with overlapping substrates, and nonspecificity/toxicity of current available inhibitors. Although MMP12 and MMP13 may be more promising targets, 37 altering the balance of MMPs and TIMPs by inhibiting FOXO3a may be more effective, such as by preventing Akt and SIRT1 downregulation.
In conclusion, we show that FOXO3a activation induces VSMC apoptosis, in part, through regulating MMP13 and MMP inhibitors to promote ECM degradation. Activation of endogenous FOXO3a, as seen in human atherosclerosis, is sufficient to induce apoptosis, MMP activation, and ECM degradation. FOXO3a activation promotes atherosclerosis and medial degeneration, together with increased necrotic cores and reduced relative fibrous cap areas, and FOXO3a and MMP13 regulate arterial remodeling. FOXO3a-induced MMP13 activation and TIMP downregulation provide an important mechanism that directly links VSMC apoptosis and ECM degradation in vascular disease.
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